Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here ...

I play a lot of competitive shooters – and I mean a lot of competitive shooters. Whether it’s being an unfortunate son in Grey Zone Warfare, flipping cards in FragPunk, or smashing and grabbing in The ...

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of ...

Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Vertex also announced enrollment completion of the IA cohort of AMPLITUDE, a global Phase 2/3 clinical trial designed to assess the impact of ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $385.74, moving +1.01% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.59% ...

Rakesh Sharma is a writer with 8+ years of experience about the intersection between technology and business. Rakesh is an expert in investing, business, blockchain, and cryptocurrencies. Amilcar has ...